J. Zugay

发表

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.

P. Darke, W. Schleif, J. Quintero, 1992, Journal of Medicinal Chemistry.

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.

D. Walters, P. Darke, W. Schleif, 1996, Journal of medicinal chemistry.

Nonpeptidal P2 Ligands for HIV Protease Inhibitors: Structure‐Based Design, Synthesis, and Biological Evaluation.

Arun K. Ghosh, D. Walters, P. Darke, 1996 .

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

P. Darke, W. Schleif, O. M. Blahy, 1994, Proceedings of the National Academy of Sciences of the United States of America.

3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Arun K. Ghosh, P. Anderson, P. Darke, 1993, Journal of the American Chemical Society.

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.

P. Darke, W. Schleif, T. Tucker, 1992, Journal of medicinal chemistry.

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

P. Darke, W. Schleif, J. Quintero, 1994, Journal of medicinal chemistry.

Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption

B. E. Evans, P. Anderson, Jiunn H. Lin, 1995 .

Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates.

L. Kuo, P. Darke, D. Hall, 1994, Biochemistry.

L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

W. M. Sanders, P. Darke, I. Sigal, 1991, Journal of medicinal chemistry.

HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.

W. M. Sanders, P. Anderson, P. Darke, 1993, Drug design and discovery.

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.

E A Emini, Arun K. Ghosh, P. Darke, 1993, Journal of medicinal chemistry.

Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration.

L. Kuo, P. Darke, J. Zugay, 1992, The Journal of biological chemistry.

Novel conformationally constrained HIV-1 protease inhibitors: rational design, enzyme inhibition, and X-ray structure of an enzyme-inhibtor complex

P. Anderson, P. Darke, J. Huff, 1994 .

Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679.

W. M. Sanders, P. Darke, I. Sigal, 1991, Journal of medicinal chemistry.

Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles

P. Anderson, P. Darke, W. Schleif, 1995 .

Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors

P. Anderson, P. Darke, W. Schleif, 1995 .

A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability

P. Anderson, P. Darke, W. Schleif, 1994 .